AU2019331913B2 - Taurolidine treatment for myc-expressing tumors in mammalian bodies - Google Patents

Taurolidine treatment for myc-expressing tumors in mammalian bodies Download PDF

Info

Publication number
AU2019331913B2
AU2019331913B2 AU2019331913A AU2019331913A AU2019331913B2 AU 2019331913 B2 AU2019331913 B2 AU 2019331913B2 AU 2019331913 A AU2019331913 A AU 2019331913A AU 2019331913 A AU2019331913 A AU 2019331913A AU 2019331913 B2 AU2019331913 B2 AU 2019331913B2
Authority
AU
Australia
Prior art keywords
taurolidine
composition
taurultam
taurinamide
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019331913A
Other languages
English (en)
Other versions
AU2019331913A1 (en
Inventor
Robert Diluccio
Bruce Reidenberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cormedix Inc
Original Assignee
Cormedix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cormedix Inc filed Critical Cormedix Inc
Publication of AU2019331913A1 publication Critical patent/AU2019331913A1/en
Application granted granted Critical
Publication of AU2019331913B2 publication Critical patent/AU2019331913B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2019331913A 2018-08-31 2019-09-03 Taurolidine treatment for myc-expressing tumors in mammalian bodies Active AU2019331913B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862725650P 2018-08-31 2018-08-31
US62/725,650 2018-08-31
PCT/US2019/049266 WO2020047530A1 (en) 2018-08-31 2019-09-03 Taurolidine treatment for myc-expressing tumors in mammalian bodies

Publications (2)

Publication Number Publication Date
AU2019331913A1 AU2019331913A1 (en) 2021-04-29
AU2019331913B2 true AU2019331913B2 (en) 2025-06-26

Family

ID=69643283

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019331913A Active AU2019331913B2 (en) 2018-08-31 2019-09-03 Taurolidine treatment for myc-expressing tumors in mammalian bodies

Country Status (7)

Country Link
EP (1) EP3843747A4 (https=)
JP (2) JP2021535167A (https=)
KR (1) KR20210054544A (https=)
CN (1) CN113226325A (https=)
AU (1) AU2019331913B2 (https=)
CA (1) CA3111100A1 (https=)
WO (1) WO2020047530A1 (https=)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001039762A2 (en) * 1999-12-06 2001-06-07 Rhode Island Hospital, A Lifespan Partner Use of taurolidine or taurultam for the manufacture of a medicament for the treatment of tumors of the central nervous system
US20040176360A1 (en) * 1999-12-06 2004-09-09 Paul Calabresi Use of taurolidine to treat tumors
US20050124608A1 (en) * 2001-04-03 2005-06-09 Redmond H. P. Treatment of cancers
US20080171738A1 (en) * 2001-04-03 2008-07-17 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Treatment of Breast Cancer
US20130089606A1 (en) * 2010-06-01 2013-04-11 Geistlich Pharma Ag Methods and compositions for oral pharmaceutical therapy
US20170196875A1 (en) * 2016-01-11 2017-07-13 Cormedix Inc. Therapeutic nanoparticles for the treatment of neuroblastoma and other cancers
WO2020047113A1 (en) * 2018-08-28 2020-03-05 Cormedix Inc. Neuroblastoma treatment with taurolidine hydrolysis products

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9005856D0 (en) * 1990-03-15 1990-05-09 Geistlich Soehne Ag Compositions
US7151099B2 (en) * 1998-07-31 2006-12-19 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Use of taurolidine and/or taurultam for treatment of abdominal cancer and/or for the prevention of metastases
GB9716219D0 (en) * 1997-07-31 1997-10-08 Geistlich Soehne Ag Prevention of metastases
US20030027818A1 (en) * 2001-04-03 2003-02-06 Redmond H. Paul Treatment of cancers
US20030092707A1 (en) * 2001-10-19 2003-05-15 Redmond H. Paul Treatment of breast cancer
CA2482687C (en) * 2003-09-29 2012-11-20 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Treatment of mesothelioma
US7964571B2 (en) * 2004-12-09 2011-06-21 Egen, Inc. Combination of immuno gene therapy and chemotherapy for treatment of cancer and hyperproliferative diseases
WO2007020509A1 (en) * 2005-08-15 2007-02-22 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Combination of methylol transfer agents with tumour-inhibiting proteins or peptides and the use thereof for the treatment of cancer or tumor growth
ES2377206T3 (es) * 2006-01-06 2012-03-23 Ed Geistlich Sohne Ag Fur Chemische Industrie Composiciones irradiadas y tratamiento de cánceres con radiación en combinación con taurolidina y/o taurultam
CA3018145C (en) * 2016-03-18 2024-09-17 Geistlich Pharma Ag TREATMENT METHOD FOR TRIPLE-NEGATIVE BREAST CANCER

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001039762A2 (en) * 1999-12-06 2001-06-07 Rhode Island Hospital, A Lifespan Partner Use of taurolidine or taurultam for the manufacture of a medicament for the treatment of tumors of the central nervous system
US20040176360A1 (en) * 1999-12-06 2004-09-09 Paul Calabresi Use of taurolidine to treat tumors
US20050124608A1 (en) * 2001-04-03 2005-06-09 Redmond H. P. Treatment of cancers
US20080171738A1 (en) * 2001-04-03 2008-07-17 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Treatment of Breast Cancer
US20130089606A1 (en) * 2010-06-01 2013-04-11 Geistlich Pharma Ag Methods and compositions for oral pharmaceutical therapy
US20170196875A1 (en) * 2016-01-11 2017-07-13 Cormedix Inc. Therapeutic nanoparticles for the treatment of neuroblastoma and other cancers
WO2020047113A1 (en) * 2018-08-28 2020-03-05 Cormedix Inc. Neuroblastoma treatment with taurolidine hydrolysis products

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: 11 May 2016 *
MÖHLER HANS ET AL: "Redox-directed cancer therapeutics: Taurolidine and Piperlongumine as broadly effective antineoplastic agents (Review)", INTERNATIONAL JOURNAL OF ONCOLOGY, vol. 45, no. 4, 1 October 2014 , pages 1329-1336 *

Also Published As

Publication number Publication date
JP2025128194A (ja) 2025-09-02
JP2021535167A (ja) 2021-12-16
EP3843747A4 (en) 2022-12-28
CN113226325A (zh) 2021-08-06
CA3111100A1 (en) 2020-03-05
WO2020047530A1 (en) 2020-03-05
AU2019331913A1 (en) 2021-04-29
KR20210054544A (ko) 2021-05-13
EP3843747A1 (en) 2021-07-07

Similar Documents

Publication Publication Date Title
EP3154590B1 (en) Combination therapy with glutaminase inhibitors
KR101267813B1 (ko) 향상된 수용해도를 갖는 라파마이신 함유 고분자나노입자 주사제형 조성물 및 그 제조방법, 및 방사선 요법과 병용하기 위한 항암 조성물
US20170266293A1 (en) Methods of treating cancers with therapeutic nanoparticles
CN101360495B (zh) 对癌症病人给药mTOR抑制剂
IL269969B2 (en) 2-pmpa protrope for healthy tissue protection during imaging or radiotherapy of psma-targeted cancer
JP2024170590A (ja) タウロリジン加水分解産物による神経芽細胞腫治療
EP3013320A1 (en) Docetaxel polymeric nanoparticles for cancer treatment
US20230390300A1 (en) Neuroblastoma treatment with taurolidine hydrolysis products
AU2019331913B2 (en) Taurolidine treatment for myc-expressing tumors in mammalian bodies
Sapra et al. Marked therapeutic efficacy of a novel polyethylene glycol-SN38 conjugate, EZN-2208, in xenograft models of B-cell non-Hodgkin’s lymphoma
US12053478B2 (en) Taurultam, taurinamide and methylene glycol treatment for MYC—expressing tumors in mammalian bodies
EP3119395B1 (en) Polymeric nanoparticles and methods of making and using same
US20080207644A1 (en) Therapeutic materials and methods
KR102314558B1 (ko) 베네토클락스의 수용성 고분자 유도체
JP7530351B2 (ja) 若年哺乳動物の身体における神経芽細胞腫を治療するための方法および組成物
CN111569078A (zh) Sirt1抑制剂在vegfr抑制剂与免疫检查点抑制剂联用引起的副作用上的应用
WO2019051141A1 (en) RADIOLUMINESCENT NANOPARTICLES FOR CONTROLLED RELEASE MEDICINES DISENGAGED BY RADIATION
US20220184219A1 (en) Method of Making Prodrug for Sustained and Controlled Release
Heller et al. Use of poly (ortho esters) in the controlled release of therapeutic agents
Li et al. Discover Nano
CN112618479A (zh) 多西紫杉醇/聚乳酸抗肿瘤植入支架的制备方法
HK40013204B (en) Bendamustine liquid compositions for use in method of treating bendamustine-responsive conditions in patients requiring reduced volumes for administration
HK1173387A (en) Use of a rapamycin derivative for the treatment of cancer
WO2001000240A2 (en) Antitumor compound
WO2008033039A1 (en) Cancer treatment

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)